Bris­tol-My­ers joins the IDO rush with its own in-house com­bo pro­gram for Op­di­vo

WASH­ING­TON, DC — While Bris­tol-My­ers Squibb joined the rush to part­ner with In­cyte on its lead­ing IDO1 drug epaca­do­stat, it’s al­so been ze­ro­ing in on its own IDO im­munother­a­py. And in­ves­ti­ga­tors turned up at AACR this year with an ear­ly look at the re­sults.

Bot­tom line: Bris­tol-My­ers is go­ing for it.

“It seems our IDO has the po­ten­tial to be one of the most po­tent in the class,” Bris­tol-My­ers on­col­o­gy de­vel­op­ment chief Faoud Namouni tells me. But it’s still ear­ly days.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.